Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial

Jr Lesher, D. E. Babel, D. M. Stewart, T. M. Jones, L. Kaminester, M. Goldman, J. S. Weintraub

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.

Original languageEnglish (US)
Pages (from-to)S20-S24
JournalJournal of the American Academy of Dermatology
Volume36
Issue number2
DOIs
StatePublished - Feb 25 1997

Fingerprint

Tinea
Therapeutics
Allylamine
butenafine
Mycoses
Antifungal Agents
Japan
Safety
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Lesher, J., Babel, D. E., Stewart, D. M., Jones, T. M., Kaminester, L., Goldman, M., & Weintraub, J. S. (1997). Butenafine 1% cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial. Journal of the American Academy of Dermatology, 36(2), S20-S24. https://doi.org/10.1016/S0190-9622(97)70318-9

Butenafine 1% cream in the treatment of tinea cruris : A multicenter, vehicle-controlled, double-blind trial. / Lesher, Jr; Babel, D. E.; Stewart, D. M.; Jones, T. M.; Kaminester, L.; Goldman, M.; Weintraub, J. S.

In: Journal of the American Academy of Dermatology, Vol. 36, No. 2, 25.02.1997, p. S20-S24.

Research output: Contribution to journalArticle

Lesher, Jr ; Babel, D. E. ; Stewart, D. M. ; Jones, T. M. ; Kaminester, L. ; Goldman, M. ; Weintraub, J. S. / Butenafine 1% cream in the treatment of tinea cruris : A multicenter, vehicle-controlled, double-blind trial. In: Journal of the American Academy of Dermatology. 1997 ; Vol. 36, No. 2. pp. S20-S24.
@article{fa07e6e797b44fb196b0a7f3376046dc,
title = "Butenafine 1{\%} cream in the treatment of tinea cruris: A multicenter, vehicle-controlled, double-blind trial",
abstract = "Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66{\%} vs 13{\%}, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81{\%} vs 13{\%}, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29{\%} vs 5{\%}, p < 0.01) and at 4 weeks after treatment (73{\%} vs 5{\%}, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.",
author = "Jr Lesher and Babel, {D. E.} and Stewart, {D. M.} and Jones, {T. M.} and L. Kaminester and M. Goldman and Weintraub, {J. S.}",
year = "1997",
month = "2",
day = "25",
doi = "10.1016/S0190-9622(97)70318-9",
language = "English (US)",
volume = "36",
pages = "S20--S24",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Butenafine 1% cream in the treatment of tinea cruris

T2 - A multicenter, vehicle-controlled, double-blind trial

AU - Lesher, Jr

AU - Babel, D. E.

AU - Stewart, D. M.

AU - Jones, T. M.

AU - Kaminester, L.

AU - Goldman, M.

AU - Weintraub, J. S.

PY - 1997/2/25

Y1 - 1997/2/25

N2 - Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.

AB - Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.

UR - http://www.scopus.com/inward/record.url?scp=0031048086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031048086&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(97)70318-9

DO - 10.1016/S0190-9622(97)70318-9

M3 - Article

C2 - 9039201

AN - SCOPUS:0031048086

VL - 36

SP - S20-S24

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -